MX2019006866A - Metodos para el uso de proteina de enlace a galectina 3 detectada en la orina para supervisar la gravedad y el progreso de nefritis lupica. - Google Patents

Metodos para el uso de proteina de enlace a galectina 3 detectada en la orina para supervisar la gravedad y el progreso de nefritis lupica.

Info

Publication number
MX2019006866A
MX2019006866A MX2019006866A MX2019006866A MX2019006866A MX 2019006866 A MX2019006866 A MX 2019006866A MX 2019006866 A MX2019006866 A MX 2019006866A MX 2019006866 A MX2019006866 A MX 2019006866A MX 2019006866 A MX2019006866 A MX 2019006866A
Authority
MX
Mexico
Prior art keywords
urine
progression
severity
methods
galectin
Prior art date
Application number
MX2019006866A
Other languages
English (en)
Inventor
Demartino Julie
Shinji Okitsu Lukas
Vlach Jaromir
Lewis Nuruddeen
Bassi Roberto
Lie Wen-Rong
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2019006866A publication Critical patent/MX2019006866A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Public Health (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Las modalidades de la presente invención describen composiciones y métodos que incorporan la medición de LGALS3BP en la orina de pacientes diagnosticados con nefritis lúpica (LN) con el propósito de supervisar la gravedad y el progreso de la LN.
MX2019006866A 2016-12-16 2017-12-18 Metodos para el uso de proteina de enlace a galectina 3 detectada en la orina para supervisar la gravedad y el progreso de nefritis lupica. MX2019006866A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662435235P 2016-12-16 2016-12-16
PCT/US2017/067114 WO2018112474A1 (en) 2016-12-16 2017-12-18 Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis

Publications (1)

Publication Number Publication Date
MX2019006866A true MX2019006866A (es) 2019-08-22

Family

ID=61022410

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006866A MX2019006866A (es) 2016-12-16 2017-12-18 Metodos para el uso de proteina de enlace a galectina 3 detectada en la orina para supervisar la gravedad y el progreso de nefritis lupica.

Country Status (13)

Country Link
US (1) US20190310250A1 (es)
EP (1) EP3555625A1 (es)
JP (1) JP7271421B2 (es)
KR (1) KR20190097128A (es)
CN (1) CN110506209B (es)
AU (1) AU2017375646A1 (es)
BR (1) BR112019010002A2 (es)
CA (1) CA3043624A1 (es)
IL (1) IL267336A (es)
MX (1) MX2019006866A (es)
RU (1) RU2019121662A (es)
SG (1) SG10202108135VA (es)
WO (1) WO2018112474A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020264410A1 (en) * 2019-06-26 2020-12-30 Sensor-Kinesis Corporation Troponin t binding agents and uses thereof
MX2022003074A (es) * 2019-09-13 2022-06-14 Memorial Sloan Kettering Cancer Center Anticuerpos anti-cd371, y usos de los mismos.
MX2022007353A (es) * 2019-12-17 2022-09-19 Univ Texas Anticuerpos novedosos ddr1 y sus usos.
JP7275405B2 (ja) 2020-02-26 2023-05-17 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体およびそれを使用する方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE388694B (sv) 1975-01-27 1976-10-11 Kabi Ab Sett att pavisa ett antigen exv i prov av kroppvetskor, med utnyttjande av till porost berarmaterial bundna eller adsorberande antikroppar
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5340721A (en) 1991-07-26 1994-08-23 Board Of Regents, The University Of Texas System Assay for free secretory component and methods for monitoring organ rejection
JP3147953B2 (ja) * 1991-10-23 2001-03-19 日本臓器製薬株式会社 生体内物質測定法
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9512994D0 (en) 1995-06-26 1995-08-30 Brf International Method for quantitative measurement of an enzyme linked immunosorbent assay
JP4436457B2 (ja) 1995-08-18 2010-03-24 モルフォシス アイピー ゲーエムベーハー 蛋白質／（ポリ）ペプチドライブラリー
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
RU2003130645A (ru) * 2001-04-03 2005-04-10 Мерк Патент ГмбХ (DE) Опухолевые маркеры карциномы почечных клеток
US20120164662A1 (en) * 2009-06-10 2012-06-28 HARA Masanori Test method on renal diseases
WO2011099012A1 (en) * 2010-02-12 2011-08-18 Yeda Research And Development Co. Ltd. Diagnosis of systemic lupus erythematosus (sle)
US20130210667A1 (en) * 2010-09-10 2013-08-15 The Ohio State University Biomarkers for Predicting Kidney and Glomerular Pathologies
EP2710143B1 (en) * 2011-05-18 2016-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for determining whether a subject is at risk of having or developing a chronic kidney disease
JPWO2013183596A1 (ja) * 2012-06-06 2016-01-28 国立大学法人名古屋大学 腎疾患のバイオマーカー及びその用途
US20140038203A1 (en) * 2012-07-09 2014-02-06 Musc Foundation For Research Development Methods for detecting or predicting kidney disease
US9809854B2 (en) * 2012-11-15 2017-11-07 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus
WO2015133484A1 (ja) * 2014-03-04 2015-09-11 国立大学法人徳島大学 腎臓疾患に関するマーカー及びその利用
CN105510592A (zh) * 2014-09-26 2016-04-20 中国医学科学院基础医学研究所 梗阻性肾病的蛋白标志物

Also Published As

Publication number Publication date
SG10202108135VA (en) 2021-09-29
US20190310250A1 (en) 2019-10-10
IL267336A (en) 2019-08-29
WO2018112474A1 (en) 2018-06-21
AU2017375646A1 (en) 2019-05-30
JP2020502507A (ja) 2020-01-23
JP7271421B2 (ja) 2023-05-11
CA3043624A1 (en) 2018-06-21
BR112019010002A2 (pt) 2019-08-20
RU2019121662A3 (es) 2021-04-22
RU2019121662A (ru) 2021-01-18
CN110506209B (zh) 2023-05-05
EP3555625A1 (en) 2019-10-23
CN110506209A (zh) 2019-11-26
KR20190097128A (ko) 2019-08-20

Similar Documents

Publication Publication Date Title
MX2019006866A (es) Metodos para el uso de proteina de enlace a galectina 3 detectada en la orina para supervisar la gravedad y el progreso de nefritis lupica.
BR112015022934A2 (pt) esteroides neuroativos, composições, e uso do mesmo
MX367046B (es) Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
EP4234583A3 (en) Evaluation and treatment of bradykinin-mediated disorders
WO2015157704A3 (en) Methods and compositions for detecting misfolded proteins
MX2021012347A (es) Composiciones, metodos y kits para el diagnostico de una neoplasia neuroendocrina gastroenteropancreatica.
SG10202006346TA (en) Integrated Ultrasonic Testing and Cathodic Protection Measurement Probe
MX2017003269A (es) Detección de las proteínas mal plegadas.
AR105618A1 (es) Metilación del promotor del ligando al receptor de muerte programada (pd-l1) en cáncer
WO2014169226A3 (en) Methods of diagnosing and treating chronic pain
EP3511422A3 (en) Methods and compositions for diagnosing, prognosing, and treating endometriosis
MX2022010954A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
AU2018253651A1 (en) Estimating material properties
EP3523639A4 (en) DETECTION REAGENTS AND ELECTRODE ARRANGEMENTS FOR DIAGNOSTIC MULTIANALYTE TEST ELEMENTS AND METHOD FOR USE THEREOF
MX2016001719A (es) Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular.
EP3851842A4 (en) ELECTROLYTE CONCENTRATION MEASURING DEVICE
EP3759469A4 (en) CHAIN TEST DEVELOPMENT DIAGNOSIS ANALYSIS
WO2017122089A8 (en) METHOD FOR MEASURING TEAR CONSISTENTS IN A TEAR SAMPLE
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
TR201900550T4 (tr) İnsan p53'ünün bir lineer epitopunu bağlayan antikor ve bunun tanısal uygulamaları.
EP3857203A4 (en) PROCEDURE FOR DETECTING THE HOOK EFFECT IN CONNECTION WITH ANAYLTS OF INTEREST DURING OR AFTER PERFORMING DIAGNOSTIC TESTS
EP3575780A4 (en) FAECAL OCCULT BLOOD TEST PAD
BR112015021507A8 (pt) métodos e composições para o diagnóstico de pré-eclampsia em uma mulher grávida e kit de ensaio de diagnóstico